US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced a significant licensing agreement with Shanghai-based LaNova Medicines Ltd, a developer of innovative cancer therapies. This deal grants Merck exclusive global rights to develop, manufacture, and commercialize LaNova’s LM-299, a novel PD-1/VEGF bispecific antibody (BsAb), marking a substantial step forward in the field of immuno-oncology.
Financial Terms and Agreement Details
As per the agreement, LaNova will receive an upfront payment of USD 588 million from Merck. Additionally, LaNova is eligible to receive up to USD 2.7 billion in milestone payments associated with the technology transfer, development, regulatory approval, and commercialization of LM-299 across multiple indications. This financial commitment underscores the potential impact of LM-299 in the treatment of various cancers.
LM-299: A Novel Bispecific Antibody
LM-299 is designed to inhibit both PD-1/PD-L1 and VEGF/VEGFR receptor signaling pathways, targeting a key immune checkpoint while also inhibiting the production of new blood vessels (angiogenesis). This dual mechanism of action addresses two critical aspects of tumor growth and immune evasion. The drug features a differentiated molecular design, comprising an anti-VEGF antibody linked to two C-terminal single domain anti-PD-1 antibodies, which may enhance its efficacy in cancer treatment.
Clinical Development Progress
A Phase I study for LM-299 is currently enrolling patients in China, indicating the advancement of this promising therapy towards clinical evaluation. The study aims to assess the safety, tolerability, and preliminary efficacy of LM-299, providing valuable data to support its further development and potential global registration.-Fineline Info & Tech
Leave a Reply